A Comparative Evaluation Optimizing Fluticasone Regimens in Allergic Rhinitis

Background: Intranasal corticosteroids are the most effective pharmacologic treatment for moderate-to-severe allergic rhinitis, but reduced-frequency regimens may improve convenience and decrease cumulative exposure. Objective: To compare the efficacy and safety of once-daily versus alternate-day fluticasone nasal spray in allergic rhinitis. Methods: This prospective randomized comparative study included 124 patients aged 6–60 years, allocated equally to once-daily fluticasone (Group 1) or alternate-day fluticasone (Group 2). The Total Nasal Symptom Score (TNSS; nasal congestion, sneezing, nasal itching and rhinorrhea; range 0–12) was recorded at baseline and weeks 4, 8 and 12. Between groups, comparisons were performed using the independent t-test or Chi-square test, as appropriate. A p-value of < 0.05 was considered statistically significant. Results: Baseline characteristics and TNSS were comparable (9.12±1.34 vs 9.25±1.41; p=0.61). Mean TNSS was lower with daily dosing at week 4 (3.42±1.21 vs 4.78±1.36; p<0.001), week 8 (2.10±1.05 vs 3.45±1.20; p<0.001) and week 12 (0.42±0.61 vs 0.78±0.89; p=0.018). At week 8, daily dosing produced higher symptom-free proportions for all four nasal symptoms. By week 12, congestion, sneezing and itching were nearly resolved in both groups, while rhinorrhea remained better controlled with daily dosing (p=0.014). No serious treatment-related adverse event was reported. Conclusion: Both regimens improved allergic rhinitis, but once-daily fluticasone achieved faster and more consistent symptom control. Alternate-day treatment may be considered only as step-down therapy in selected, well-controlled patients.

Authors

Institutions

Publication Details

Journal
International Journal of Drug Delivery Technology
Published
2026-11-19
DOI
https://doi.org/10.25258/ijddt.16.81s.4
Primary Topic
Allergic Rhinitis and Sensitization
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Comparative Evaluation Optimizing Fluticasone Regimens in Allergic Rhinitis

Nitha Nitha, Thyvalath Divya Ramesh, Nikhat Anjum, Snigdha Lakka et al.
International Journal of Drug Delivery Technology
Allergic Rhinitis and Sensitization
article

A Comparative Evaluation Optimizing Fluticasone Regimens in Allergic Rhinitis

Nitha Nitha, Thyvalath Divya Ramesh, Nikhat Anjum, Snigdha Lakka, Gomathi R
article en

Abstract

Background: Intranasal corticosteroids are the most effective pharmacologic treatment for moderate-to-severe allergic rhinitis, but reduced-frequency regimens may improve convenience and decrease cumulative exposure. Objective: To compare the efficacy and safety of once-daily versus alternate-day fluticasone nasal spray in allergic rhinitis. Methods: This prospective randomized comparative study included 124 patients aged 6–60 years, allocated equally to once-daily fluticasone (Group 1) or alternate-day fluticasone (Group 2). The Total Nasal Symptom Score (TNSS; nasal congestion, sneezing, nasal itching and rhinorrhea; range 0–12) was recorded at baseline and weeks 4, 8 and 12. Between groups, comparisons were performed using the independent t-test or Chi-square test, as appropriate. A p-value of < 0.05 was considered statistically significant. Results: Baseline characteristics and TNSS were comparable (9.12±1.34 vs 9.25±1.41; p=0.61). Mean TNSS was lower with daily dosing at week 4 (3.42±1.21 vs 4.78±1.36; p<0.001), week 8 (2.10±1.05 vs 3.45±1.20; p<0.001) and week 12 (0.42±0.61 vs 0.78±0.89; p=0.018). At week 8, daily dosing produced higher symptom-free proportions for all four nasal symptoms. By week 12, congestion, sneezing and itching were nearly resolved in both groups, while rhinorrhea remained better controlled with daily dosing (p=0.014). No serious treatment-related adverse event was reported. Conclusion: Both regimens improved allergic rhinitis, but once-daily fluticasone achieved faster and more consistent symptom control. Alternate-day treatment may be considered only as step-down therapy in selected, well-controlled patients.

International Journal of Drug Delivery TechnologyVol. 16(81s)
Adichunchanagiri University (IN)
Allergic Rhinitis and Sensitization
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon